Angulo-Molina Aracely, Reyes-Leyva Julio, López-Malo Aurelio, Hernández Jesús
a Departamento de Ciencias de la Salud , Universidad de las Américas Puebla , Puebla , México.
Nutr Cancer. 2014;66(2):167-76. doi: 10.1080/01635581.2014.863367. Epub 2013 Dec 23.
In recent years, efforts to improve cancer therapy have focused on developing new anticancer agents, such as mitocans. These agents include vitamin E analogues and suppress cancer by inducing apoptosis by targeting mitochondria. Alpha tocopheryl succinate (α-TOS) is the most effective form of vitamin E analogues causing inhibition of proliferation and apoptosis of cancer cells. Both in vitro and in vivo studies have demonstrated that α-TOS selectively kills tumor cells with little or no effect on normal cells. Treatment with α-TOS shows great promise for future clinical applications, as it causes cell death, at least in part, by selectively inducing apoptosis by mitochondrial destabilization. This review presents an overview of perspectives on α-TOS and the potential uses of α-TOS in cancer treatment and other clinical applications.
近年来，改善癌症治疗的努力主要集中在开发新的抗癌药物，如米托蒽醌类。这些药物包括维生素E类似物，通过靶向线粒体诱导细胞凋亡来抑制癌症。琥珀酸生育酚（α-TOS）是最有效的维生素E类似物形式，可抑制癌细胞的增殖并诱导其凋亡。体外和体内研究均表明，α-TOS能选择性地杀死肿瘤细胞，对正常细胞几乎没有影响。α-TOS治疗在未来临床应用中显示出巨大潜力，因为它至少部分地通过线粒体不稳定选择性诱导细胞凋亡而导致细胞死亡。本文综述了关于α-TOS的观点以及α-TOS在癌症治疗和其他临床应用中的潜在用途。
